The human polyomaviruses, BKV and JCV, were ®rst isolated 30 years ago, BKV from the urine of a renal transplant patient (Gardner et al., 1971) and JCV from the brain of a patient with progressive multifocal leukoencephalopathy (PML) (Padgett et al., 1971 ), a neurodegenerative disease in which glial cells, the cells that produce myelin, are destroyed. These viruses share much in common with their well-studied simian cousin, SV40, but each also has its own unique features that distinguish it from the monkey virus. In this review, I will provide a brief overview of the biology of the two human viruses, an analysis of their transforming potential and their oncoproteins, the T antigens, and a discussion of the possible role of these viruses in human cancer.
JCV and BKV are small, non-enveloped particles with an icosahedral capsid consisting of three viral proteins, VP1, VP2, and VP3, and containing a double stranded, circular chromosome that is approximately 5.4 kb in length. They enter the cell through an as-yet undetermined receptor, and are transported to the nucleus where the DNA is uncoated and the viral transcription program begins. The early transcription unit is the ®rst to be expressed, and produces a series of alternatively spliced mRNAs that encode the major tumor antigens of the virus, the most well studied of which are large T antigen and small t antigen. These two proteins are identical in their amino termini but have distinct carboxy termini as a result of the use of alternative RNA splice acceptors (Figure 1) . A number of other minor species, also derived by dierential premRNA splicing, have been reported in JCV and BKV (Bollag et al., 1989; Trowbridge and Frisque, 1995) . One of these, a 17 kDa protein called T' that shares its ®rst 131 amino acids with T antigen and then terminates after 4 or 5 unique amino acids, has also been identi®ed in SV40 (Zerrahn et al., 1993) (Figure  1) .
When large T antigen (hereafter referred to as T antigen) accumulates to high enough levels, it recruits the host DNA polymerase to the viral origin of DNA replication, where it also unwinds the DNA and allows initiation to take place (Waga et al., 1994) . At the same time, T antigen represses early gene transcription and stimulates late gene expression. The late capsid proteins are also expressed from a series of alternatively spliced mRNAs. Once the DNA has been replicated and the structural proteins are produced, new viral particles are assembled and are released from the cell. The exact mode of egress is unclear at this time. Readers wishing more detail on the basic biology of the polyomaviruses are referred to the comprehensive review by Cole in Fields Virology (Cole, 1996) .
The mode of transmission of BKV and JCV among individuals has not been de®ned, although one can surmise possibilities based on their epidemiology. The fact that most individuals seroconvert during childhood (Gardner, 1973, Padgett and Taguchi et al., 1982) , along with the detection of JCV in tonsillar tissue (Goudsmit et al., 1982; Monaco et al., 1998) , supports a respiratory route. One possibility is that the primary site of infection is the upper respiratory tract, with viral replication taking place followed by viremia to the target organs in the urinary tract and, in the case of JCV, brain. At these target organs, the virus establishes a subclinical persistent infection that is held in check by a normal immune system. Viral replication and disease is usually only seen in immunocompromised individuals including pregnant women, transplant patients on immunosuppressive drugs, and AIDS patients. In these persons, BKV is most commonly associated with hemorrhagic cystitis, a serious disease of the bladder (deVries and Freiha, 1990) , and JCV is the causal agent of PML (Weber and Major, 1997) . JCV strains are classi®ed as archetypal or rearranged, based on the structure of their transcriptional control regions (TCRs). The archetypal TCR contains a single copy of the promoter and enhancer, and as their name implies the rearranged strains contain rearrangements, usually deletions and duplications, in this region (Ault and Stoner, 1993; Yogo et al., 1990 Yogo et al., , 1991 . The archetypal strains can be isolated from both normal individuals and immunocompromised patients, and therefore are believed to be the viruses that spread throughout the population (Agostini et al., 1996; Ault and Stoner, 1993; Ciappi et al., 1999; Flaegstad et al., 1991; Guo et al., 1996; Kitamura et al., 1994; Kunitake et al., 1995; Markowitz et al., 1991; Sugimoto et al., 1997; Tominaga et al., 1992; White et al., 1992; Yogo et al., 1990) . Rearranged strains of the virus have mainly been isolated from PML patients, although they are occasionally found in non-aected individuals (Ault and Stoner, 1993; Ciappi et al., 1999; Dorries et al., 1994; Elsner and Dorries, 1998; Kato et al., 1994; Loeber and Dorries, 1988; Martin et al., 1985; Newman and Frisque, 1999; White et al., 1992; Yogo et al., 1994) . Although this aspect of BKV biology has not been studied in as much detail, isolates of this virus also appear to fall into the same two general classes (Negrini et al., 1991; Rubinstein et al., 1987 Rubinstein et al., , 1991 . These DNA rearrangements, at least in the case of JCV, lead to higher levels of expression of T antigen and, consequently, more viral replication.
The de®nition of JCV and BKV as tumor viruses derives from their behavior in both in vivo and animal models. It was demonstrated early on that BKV and JCV T antigens will transform rodent cells in culture, and they can immortalize human cells alone or in the presence of other oncogenes including ras, myc, and adenovirus E1A (Frisque et al., 1980; Grossi et al., 1982; Howley et al., 1980; Pater and Pater, 1986, Portolani et al., 1978; Purchio and Fareed, 1979; Shah et al., 1976; Takemoto et al., 1979; Vasavada et al., 1986) . In comparative studies, it has been demonstrated that BKV T antigen is more ecient than JCV T antigen in such in vitro assays, although both are less ecient than SV40 (Bollag et al., 1989; Haggerty et al., 1989; Tavis et al., 1994; Trowbridge and Frisque, 1993) . Tumors arise in transgenic animals expressing the viral T antigens. Mice containing the BKV early region develop hepatocellular carcinoma and renal tumors (Dalrymple and Beemon, 1990; Small et al., 1986) , and those with the early region of a rearranged strain of JCV isolated from PML, JCV(Mad), develop adrenal neuroblastomas (Small et al., 1986) or poorly dierentiated tumors of possible neuroectodermal origin (Franks et al., 1996) . Most recently, the early region of an archetypal strain of JCV was used to produce transgenic mice. Fifty per cent of these mice demonstrated neurologic illness as they approached 1 year of age. A detailed pathological analysis indicated that the mice did not have any apparent abnormalities in their glial cells or in myelin production, as would be found in human PML; rather, they developed primitive neuroectodermal tumors . Interestingly, the tumor cells expressed higher levels of T antigen than did cells in the hindbrains of normal transgenic mice. When hamsters are injected with JCV, they also develop brain tumors ZuRhein, 1983) .
Large T antigen orchestrates major changes in cell physiology that ultimately may lead to oncogenesis. The ®rst step in this process is the induction of cells to enter S phase. Since the polyomaviruses do not encode any DNA synthetic machinery, they are dependent on the host's machinery to replicate their DNA genomes. The viruses normally infect cells that are not actively dividing, such as respiratory or urinary epithelial cells, lymphocytes, or glial cells, however, and these cells do not synthesize DNA replication enzymes and other cofactors. As a result, the viruses trick the cell into thinking it itself wants to divide. T antigen accomplishes this deception by binding to and inactivating the function of the retinoblastoma family of tumor suppressor proteins, pRb, p107, and p130. The ability to bind these proteins has been demonstrated both in vivo and in vitro (Dyson et al., 1989a (Dyson et al., , 1990 Harris et al., 1996; Howard et al., 1998; Krynska et al., 1997) , and maps to a region of the T antigen molecule that is encoded near the amino terminal end of the sequences just 3' of the splice acceptor, meaning they are present in the large T and T' antigens, but not in small t antigen (see Figure 1 ). This domain contains the consensus sequence, LXCXE, which is present in a number of viral proteins that share a common function with T antigen, such as the adenovirus E1A and human papillomavirus (HPV) E7 proteins, as well as the T antigens of SV40 and mouse polyomavirus (Chellappan et al., 1992; DeCaprio et al., 1988; Dyson et al., 1989b Dyson et al., , 1992 Ewen et al., 1989; Freund et al., 1992; Harris et al., 1998b; Moran, 1988; Munger et al., 1989; Vousden and Jat, 1989) . Binding of the BKV and JCV T antigens to the pRb family proteins is required for deregulation of cell growth in culture (Harris et al., 1996; Tavis et al., 1994) . Simple binding to these proteins is not sucient for transformation, however, which requires a second domain of the T antigen molecule called the J domain. So-named due to its homology with the DnaJ family of molecular chaperones (Brodsky and Pipas, 1998; Campbell et al., 1997; Kelley and Georgopoulos, 1997; Stubdal et al., 1997) , it has been demonstrated that this domain mediates the degradation of pRb family members by BKV T antigen (Harris et al., 1998b) . The consequences of the interaction between JCV T antigen and the pRb family Figure 1 Schematic diagram of the viral tumor antigens. The mRNAs encoding small t, large T, and the 17 kDa T' antigens are indicated by the boxes, with the V-shaped lines representing introns that are spliced out. The gray shading indicates sequences that are common to all the T antigens, windowpanes those common to large T and the 17 kDa T' the black box those unique to the 17 kDa T', and hatching those unique to small t antigen. Open boxes are untranslated sequences proteins has not been studied in as much detail, but it does deregulate cyclin/Cdk (cyclin dependent kinase) activity, preventing cells from exiting the cell cycle (Tretiakova et al., 1999) . The end result of this interaction between T antigen and the cellular tumor suppressor proteins is the release of E2F transcription factors from the pRb family proteins. pRb family-E2F complexes repress the transcription of a series of genes involved in S phase progression and DNA synthesis, while free E2Fs activate these genes and allow the cell to enter S phase (for review see Cress and Nevins, 1996) . This attempt at unscheduled entry into S phase is somehow sensed by the cell, which responds with an apoptotic program. At this point, another T antigen function comes into play, namely the ability to bind to and inactivate the p53 protein (Bollag et al., 1989; Haggerty et al., 1989a; Harris et al., 1998a) . This function maps to the carboxy terminus of the T antigen molecule (for review see Pipas and Levine, 2001 ). Binding to p53 stabilizes the p53 protein but also prevents it from activating its target cellular promoters. Consequently, cells expressing T antigen do not undergo p53-mediated cell cycle arrest or apoptosis. From the virus's point of view, this mechanism has evolved to keep the cell alive as long as possible during a productive infection in order to maximize the yield of progeny virions. Unfortunately for the cell which provides an environment that is non-permissive for infection, or the cell in which rearrangements in the viral chromosome interfere with replication, these same mechanisms can lead to oncogenesis.
T antigen plays a third role in oncogenesis, in that it induces chromosomal damage, although how it does so is not understood (Ray et al., 1990; Theile and Grabowski, 1990; Tognon et al., 1996; Trabanelli et al., 1998) . In one study, it was reported that increased chromosomal damage in vivo correlates with high titers of antibodies against the viruses, particularly JCV (Lazutka et al., 1996) . As a whole, then, T antigen induces resting cells to enter the cycle, blocks cell cycle arrest and apoptosis, and is potentially mutagenic, making it a formidable oncoprotein. Studies on SV40 small t antigen demonstrate that it also plays a role in transformation under certain conditions (Mungre et al., 1994; Pallas et al., 1990) . This protein exerts its main eect through an inhibitory interaction with PP2A, a protein phosphatase that regulates signal transduction pathways in the cell (Sontag et al., 1993; Yang et al., 1991) . While the small t molecules of BKV and JCV have not been studied in much detail at all, it is reasonable to assume based on sequence identity that they function similarly to SV40 small t antigen. A recent report has examined the 17 kDa T' proteins of JCV and compared their pRb family protein binding characteristics to those of large T antigen (Bollag et al., 2000) . These studies demonstrate that there are dierences among the relative anities of the dierent T antigens for the various pRb family proteins, and that these T antigens have dierential eects on the steady state levels and phosphorylation patterns of the cellular proteins. Since the function of the pRb family proteins is controlled by their phosphorylation state (Classon and Dyson, 2001; Nevins, 2001) , one can imagine that altering relative levels of expression of the various T antigens in the cell could have signi®cant eects on the cell cycle characteristics of the cell.
Evidence supporting a possible role for JCV and BKV in human cancer has accumulated slowly in recent years. Work in the area received a boost with the advent of PCR technology, which allowed investigators to examine even small biopsy samples for the presence of viral sequences. Both viruses are clearly tumor viruses, and both are ubiquitous in the population, so hypothesizing that they may contribute to cancer is not very far-fetched. Most recently, T antigen expression has been demonstrated in some tumor samples. Data establishing a truly causal role for either virus in cancer, however, have not yet been obtained. The available data are summarized in the following paragraphs.
One must use care during PCR-based detection of viral sequences in biopsy samples. This is because the small amount of sample available from some biopsies means having to perform high numbers of cycles in the reaction, resulting in an increased susceptibility to false positives due to laboratory contamination. Indeed, one may question the validity of some of the earlier reports. More recently, however, most laboratories have been very vigilant in isolating the various steps in the PCR process so as to avoid sample contamination. Moreover, contamination can be ruled out by sequencing the products from the tissue isolates and demonstrating that they are dierent from laboratory strains, or by employing other techniques that are not susceptible to contamination such as immunohistochemistry or Southern blotting (when enough sample is available). Another issue with PCR, however, is that biopsy samples are not pure populations of cells: a small number of virus-positive normal cells in a tumor sample, for example, can make the tumor look positive. This is a distinct possibility given the widespread prevalence of the two viruses in the population.
BKV DNA sequences have been reported in a range of human tumors, many of which do not ®t the normal spectrum of anatomical sites thought to be infected by the virus, including rhabdomyosarcoma, lung, Kaposi's sarcoma, pancreas, liver, brain, and various urinary tract neoplasms (Barbanti-Brodano et al., 1987; Caputo et al., 1983; Corallini et al., 1987; De Mattei et al., 1995; Dorries et al., 1987; Fiori and Di Mayorca, 1976; Flaegstad et al., 1999; Monini et al., 1995a Monini et al., ,b, 1996 Negrini et al., 1990; Pater et al., 1980) (for review see Imperiale, 2000) . Another study found no evidence for BKV in brain tumors (Arthur et al., 1994) . Two of these BKV reports have provided molecular evidence above and beyond PCR analysis. One group of investigators did detect BKV sequences by PCR in greater than 50% of both normal and tumor tissue derived from the urinary tracts of patients (Monini et al., 1995b) . This number is supported by the prevalence of BKV in the population, which is at least 70%. In addition, the urinary tract seems a likely place to ®nd the virus since it is known to persist in the kidney. What this report also demonstrated, however, was that there was enough viral DNA present in six of the approximately 70 tumors examined to be detected by Southern blotting, but not in any of the normal tissues. This means either that the viral chromosome was ampli®ed in the tumors, or that there was selection in the tumor for cells containing BKV. The evidence favors the second explanation, as the viral sequences were integrated into the host chromosome in all six tumors examined, with just one containing episomal copies, although in four of the six tumors the copy number was less than one. These investigators also sequenced the viral origin of replication from nine abnormal samples. All the sequences were identical (except for two point mutations in one of the samples), representing a new strain of BKV which they designated URO1. It is intriguing that this strain contains rearrangements in the origin region, as these might aect viral DNA replication. It is known, for example, that disruptions in this region alter replication ability and increase transformation potential in cell culture assays (Rubinstein et al., 1991; Yoshiike, 1982, 1985) . Also, as discussed above, such rearrangements could enhance the transcriptional activity of the viral promoter. A block to replication would prevent killing of the host cell and rather lead to transformation if T antigen were to be expressed continually, much the same as that which occurs during transformation of non-permissive cells by wild type polyomaviruses (Butel, 1986) or of permissive cells by viral chromosomes whose origin of replication has been mutated (Gluzman, 1981) . Whether the mutations in URO1 have this same eect on replication or transformation remains to be determined. In a second report, BKV DNA sequences were detected in 17/18 neuroblastomas by in situ hybridization, T antigen was found in 16/18 of the tumors by immunohistochemistry, and T antigen-p53 complexes were demonstrated by immunoprecipitation of proteins isolated from two neuroblastoma samples (Flaegstad et al., 1999) . Others have also reported BKV sequences in neuroblastoma, but by PCR (De Mattei et al., 1995) . Additional work will be required to determine the signi®cance of this ®nding, which leaves unanswered questions such as whether T antigen is interfering with p53 function and truly aecting the growth characteristics of these cells, and how BKV is reaching the CNS.
Speculating that a virus might account for some of the chromosomal instability seen in colorectal tumors, investigators have looked for JCV sequences in such tumors and found them (Laghi et al., 1999) . It is of note that this group increased their ability to detect the virus by treating their samples with topoisomerase prior to PCR ampli®cation. Presumably, this relaxes the supercoiled viral genome, making it more accessible to the amplifying polymerase. While this result leaves the same open question as for BKV above, namely how the virus got there, the investigators did rule out the likelihood of contaminating lymphocytes as the source of the JCV. Most recently this same laboratory has sequenced the transcription control region of their isolates and ®nd them to be of Mad-1, a nonarchetypal strain (Ricciardiello et al., 2001) . JCV variants have also been reported to be found in human brain tumors. One group has begun to examine human medulloblastomas for the presence of JCV . In a study on a small number of tumors, approximately two-thirds contained early region sequences and almost all contained late region sequences. Immunohistochemical staining for T antigen demonstrated that approximately 5 ± 20% of the tumor cells in a fraction (one-fourth) of the DNA-positive samples made detectable protein. VP1, the major viral capsid protein expressed during the late phase of a productive infection, was not detected, indicating that lytic replication is not occurring. As is the case for BKV described above, a block to replication of the virus, concomitant with T antigen expression, could lead the cell down the path to oncogenicity.
With evidence accumulating that BKV and JCV are present in human tissues, one must ask what the next steps should be in order to con®rm or refute a role for these viruses in the molecular pathogenesis of disease. Several points are clear. The viruses are found throughout most human populations and viral sequences can be found in a subset of human tumors. We know from the in vitro and animal studies cited above that the T antigens disrupt normal cell growth control. Thus, there is certainly the potential for the viruses to contribute to tumor induction and/or progression. Ideally, one would like to see T antigen expression in every tumor cell for a given sample, although it is possible that the T antigen-positive cells secrete paracrine growth signals that could act on neighboring cells. Either way, one would predict that inhibiting T antigen expression would reverse the growth of these tumor cells. This has been shown to be the case for an SV40-positive mesothelioma cell line, for example: overexpression of an antisense RNA reverted the abnormal growth phenotype (Waheed et al., 1999) . One might also expect that T antigen-induced tumors would not carry mutations in their RB1 or p53 genes, similar to the case of HPV-induced cervical carcinomas (Choo and Chong, 1993; Iwasaka et al., 1993; Schener et al., 1991) . The argument here is that the viral oncoprotein (or proteins, in HPV) substitutes for mutations in these cellular tumor suppressor genes by functionally inactivating the gene products. Approaches such as microarray analysis of virus positive and virus negative tumors might lend insights into molecular ®ngerprints that are characteristic of the presence of virus. Proving a causative role for either virus is clearly going to require additional analyses.
In addition to the continued examination of pathological specimens, more studies on the molecular biology of the human viruses are sorely needed. Many have assumed that JCV and BKV would behave identically to other small DNA viruses, particularly to SV40, with respect to their oncogenic transforma-tion properties. There are already indications, as mentioned above, that dierences exist in how BKV and JCV T antigens interact with cell growth control pathways. Therefore, it is important to continue a detailed analysis of the JCV and BKV T antigens. Moreover, one must not forget the possibility that the small t and 17 kDa T' antigens of these viruses might play a signi®cant role in their pathogenesis. It should be noted that much of what we know about SV40 transformation, for example, comes from studies in non-permissive hosts. The interplay between JCV and BKV and human cells might be much dierent, as they seem to have evolved to co-exist with their human hosts without causing overt disease under most circumstances. Future investigations of the molecular biology of these two viruses should be aimed at providing insights into how they switch from benign, persistent pathogens to virulent bugs that cause acute diseases such as cystitis, and PML and, potentially, cancer.
